|
Bradley Anderson,
Ph.D.
Chair, Division of Pharmaceutical
Sciences
H.B. Kostenbauder Professor in Pharmaceutical Sciences
RESEARCH ACTIVITIES
Permeability in Lipid
Bilayer Membranes
Dr. Anderson's lab is developing theory and
conducting experiments using liquid crystalline bilayer membranes to
account for the effects of permeant structure, lipid bilayer
composition, and environmental conditions on drug permeability across
lipid bilayers. The results of this effort are expected to be
fundamental to understanding biomembrane and cell function, inasmuch as
a primary function of bilogical membranes is to selectively limit or
permit permeation of various agents.
Enzyme-based Strategies
for CNS Delivery of AIDS Drugs
The prevalence of a progressive
deterioration in mental function accompanying AIDS, referred to as AIDS
dementia complex, its association with HIV infection in the central
nervous system (CNS), and the extremely low CNS penetration of some
dieoxynucleosides currently approved or under development suggests the
need for rational approaches for increasing CNS penetration of these
agents. The development of in vitro/in situ models to better understand
and predict the limited CNS availability and limited oral
bioavailability of CNS-targeted prodrugs of dideoxynucleosides and
protease inhibitors is the current focus of this research.
Drug Decomposition in the
Amorphous Solid-State
Deamidation and covalent aggregate
formation are important reactions limiting the shelf life of a variety
of peptide and protein lyophilized products. The mechanisms for these
processes in the amorphous solid state and the utility of solution
kinetics data to predict processes in amorphous solids are currently the
focus of these studies.
Development of Dosage
Forms and Delvery Systems for Agents Useful in the Treatment of AIDS and
Cancer
As part of a nationwide program under the
direction of the National Cancer Institute to identify and clinically
evaluate new drug candidates active in treating AIDS and cancer, our
laboratory is responsible for the preformulation and the design of
prototype parenteral formulations of new candidates entering the system.
First-year graduate students receive valuable training in physical and
analytical chemistry through their participation on this project.
Preclinical Drug
Evaluation Facility
The Preclinical Drug Evaluation Facility (PDEF)
is a core facility that provides pharmaceutical formulation,
pharmacokinetics, biopharmaceutics, toxicological and limited
pharmacological evaluation of new materials and drug candidates for
University as well as outside investigators who need support in the area
of translational therapeutics. The laboratory is the site for two of the
four arms of the facility, which is jointly administered by Dr. Anderson
and by Dr. Jack Taylor of the University of Utah. The PDEF continues the
work begun by Dr. Anderson as professor in the Department of
Pharmaceutics at the University of Utah College of Pharmacy.
|
